CCT129202 is a representative of a structurally novel series of imidazopyridine small-molecule inhibitors of Aurora kinase activity. It shows high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines.
|Aurora A||Aurora B||Aurora C|
|42 nM||198 nM||227 nM|
|In vitro (25°C)||DMSO||3 mg/mL (6.03 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
|In vivo||1% DMSO/30% polyethylene glycol/1% Tween 80||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||20.12 mL||100.6 mL||201.21 mL|
|0.5 mM||4.02 mL||20.12 mL||40.24 mL|
|1 mM||2.01 mL||10.06 mL||20.12 mL|
|5 mM||0.4 mL||2.01 mL||4.02 mL|
*The above data is based on the productmolecular weight 497.0 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|